Alves, Ana CatarinaEtxebarria, AitorMedeiros, Ana MargaridaBenito-Vicente, AsierThedrez, AuréliePassard, MaximeCroyal, MikaëlMartin, CesarLambert, GillesBourbon, Mafalda2016-02-022016-02-022015-11-10J Am Coll Cardiol. 2015 Nov 10;66(19):2152-4. doi: 10.1016/j.jacc.2015.08.871. Epub 2015 Nov 2.2045-2322http://hdl.handle.net/10400.18/3277LetterGain of function (GOF) mutations in proprotein convertase subtilisin kexin type 9 (PCSK9) are a rare cause of familial hypercholesterolemia (FH). We identified a child with a clinical diagnosis of FH with 2 novel putative PCSK9 GOF missense variants (p.[(Ala62Asp)]; [(Pro467Ala)]), and no mutation in the low-density lipoprotein (LDL) receptor (LDLR) or in apolipoprotein B100 (APOB) genes. The proband was referred to the Portuguese FH Study (1) at age 11 and presented a total cholesterol of 316 mg/dl and low-density lipoprotein cholesterol (LDL-C) of 234 mg/dl on a strict diet. The phenotype presented by all PCSK9 heterozygous carriers within this large pedigree is similar to APOB heterozygous carriers (LDL-C, 198.75 ± 14.98 mg/dl vs. LDL-C, 211.57 ± 42.02 mg/dl; p = 0.227) but significantly different than heterozygous LDLR carriers (LDL-C, 198.75 ± 14.98 mg/dl vs. LDL-C, 230.63 ± 76.50 mg/dl; p = 0.012) when comparing the relatives’ phenotype in our cohort.engFamilial HypercholesterolemiaHomozygotePCSK9PCSK9 protein, humanDNA/geneticsDNAPortugalDoenças Cardio e Cérebro-vascularesHipercolesterolemia Familiarjournal article10.1016/j.jacc.2015.08.871